Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra

 
• By Sue Sutter

Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.
Pfizer's Ixifi is the first US approval of a biosimilar wholly developed by the big pharma.

More from New Products

More from Scrip